OP0302 RUZINURAD FOR HYPERURICEMIA ASSOCIATED WITH PRIMARY GOUT: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, PHASE 3 STUDY

医学 高尿酸血症 痛风 内科学 多中心研究 随机对照试验 尿酸
作者
H. Ding,C. Bao,J. Hu,L. Qian,Lan‐Yan Yang,Z. Wang,Zheng Fu,Nai-Ning Zhang,C. Lin,Chongbo Zhao,Lingyun Sun,R. Li,Wei Chen,Wei He,X. Yu,Jie Li,H. Chen,Yi Liu,Zhangwei Chen,X. Xu
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:84: 240-241 被引量:3
标识
DOI:10.1016/j.ard.2025.05.304
摘要

Background: Uric acid transporter 1 (URAT1) is responsible for the reabsorption of approximately 90% of uric acid (UA) in the kidneys [1]. Inhibitors targeting URAT1 can effectively increase the excretion of uric acid, thereby reducing serum UA (sUA) levels. Ruzinurad is a highly selective and potent inhibitor against URAT1. In previous phase 1 and phase 2 studies, ruzinurad was well-tolerated and showed robust sUA lowering effect in patients with hyperuricemia [2]. Objectives: We further conducted a phase 3 study to assess the efficacy and safety of ruzinurad versus allopurinol in patients with hyperuricemia associated with primary gout (NCT04956432). Methods: This was a multicenter, randomized, double-blind, active-controlled, phase 3 study consisting of a 3-week screening period, a 16-week double-blind core treatment period, a 36-week open-label extension treatment period, and a 4-week follow-up period (Figure 1). Gout adults with fasting sUA ≥480 µmol/L were randomly assigned (1:1) to the ruzinurad or allopurinol groups, stratified by the last estimated glomerular filtration rate (eGFR) at screening (≥60 to <90 mL/[min×1.73 m 2 ] or ≥90 mL/[min×1.73 m 2 ]) and the last sUA level at screening (≥480 to <540 μmol/L or ≥540 μmol/L). Treatment administration in the ruzinurad and allopurinol groups was initiated at 1 mg/day and 100 mg/day, followed by dose titration to 10 mg/day and 300 mg/day, respectively (Figure 1). All study medications were taken orally once daily. The primary endpoint was proportion of patients with the last two sUA levels both ≤360 μmol/L at Week 16. Results: A total of 773 patients received study treatment during the core treatment period, with 388 in the ruzinurad group and 385 in the allopurinol group. Baseline characteristics were generally balanced among the ruzinurad and allopurinol groups (male, 98.7% vs. 98.7%; median age, 35.0 vs. 36.0 years; median sUA, 576.5 vs. 568.0 μmol/L; eGFR <90 mL/(min×1.73 m 2 ), 34.8% vs. 35.3%; median creatinine, 83.0 vs. 82.0 μmol/L; absence of tophi, 85.3% vs . 87.0%; prior use of urate-lowering medications, 64.4% vs. 67.0%). At Week 16, significantly greater proportions of patients in the ruzinurad group achieved the target sUA level of ≤360 μmol/L at the last two monthly measurements, compared with the allopurinol group (39.7% [95% CI, 34.8% to 44.8%] vs. 26.5% [95% CI, 22.2% to 31.2%]; treatment difference, 13.1% [95% CI, 6.6% to 19.7%]; one-sided p <0.0001). Proportion of patients achieving sUA level of ≤360 μmol/L at Week 16 was greater in the ruzinurad group (52.6% vs. 34.5%; one-sided nominal p <0.0001), which was maintained until Week 52 (the end of extension treatment period; 54.2% in the ruzinurad group vs. 31.0% in the allopurinol group; Figure 2). During the 52-week treatment period, treatment-emergent adverse events (TEAEs) occurred in 348 (89.7%) and 353 (91.7%) patients in the ruzinurad and allopurinol groups, respectively, with the most common (≥20%) being gout flares (51.0% vs. 43.6%), increased alanine aminotransferase (21.6% vs. 29.4%), upper respiratory tract infection (21.4% vs. 19.0%), and increased blood creatinine (20.1% vs. 9.6%). The majority of TEAEs were mild or moderate. Serious TEAEs occurred in 4.9% and 3.1% of patients in the ruzinurad and allopurinol groups, respectively. Conclusion: The URAT1 inhibitor ruzinurad demonstrated superior sUA lowering effect over allopurinol, along with a well-tolerated safety profile, in patients with hyperuricemia associated with primary gout. REFERENCES: [1] So A, Thorens B. Uric acid transport and disease. J Clin Invest. Jun 2010;120(6):1791-9. doi:10.1172/jci42344 [2] Lin Y, Chen X, Ding H, et al. Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study. Rheumatology. 2021;60(11):5089-5097. Acknowledgements: NIL . Disclosure of Interests: Huihua Ding: None declared, Chunde Bao: None declared, Jiankang Hu: None declared, Long Qian: None declared, Lei Yang: None declared, Zhongming Wang: None declared, Zili Fu: None declared, Ning Zhang: None declared, Changsong Lin: None declared, Cheng Zhao: None declared, Lingyun Sun: None declared, Rongshan Li: None declared, Wenli Chen: None declared, Hua Wei: None declared, Xiaoxia Yu: None declared, Juan Li: None declared, Haibing Chen: None declared, Yuan Liu: None declared, Zhiyong Chen: None declared, Xiaoyan Xu: None declared, Yuan Xue: None declared, Yongjun Mei: None declared, Dong Zhao: None declared, Rui Yan: None declared, Min Zhang: None declared, Bin Zhou: None declared, Jia Chen: None declared, Jing Liu: None declared, Zhenyu Jiang: None declared, Zhanqing Gu: None declared, Haoshu Cui Jiangsu Hengrui Pharmaceuticals Co., Ltd., Yanlin Ma Jiangsu Hengrui Pharmaceuticals Co., Ltd. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
张未来发布了新的文献求助10
刚刚
刘六六发布了新的文献求助10
1秒前
2秒前
七七完成签到 ,获得积分10
2秒前
2秒前
神勇迎夏完成签到,获得积分10
2秒前
3秒前
所所的应助被YAYA采纳,获得10
3秒前
张伟发布了新的文献求助10
3秒前
SYNU刘平瀚发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
科研通AI6.2的应助被chengzi采纳,获得10
3秒前
CipherSage的应助被HH采纳,获得10
3秒前
3秒前
3秒前
3秒前
3秒前
4秒前
4秒前
乐乐的应助被灰灰采纳,获得10
4秒前
4秒前
向着阳光奔跑完成签到,获得积分10
5秒前
采花大盗完成签到,获得积分10
5秒前
非官方个姐完成签到,获得积分10
5秒前
6秒前
共享精神的应助被骰子六采纳,获得10
6秒前
orixero的应助被安澜宁采纳,获得30
7秒前
hongjing发布了新的文献求助10
7秒前
7秒前
sakiecon完成签到,获得积分10
7秒前
英俊的铭的应助被威武的映真采纳,获得10
7秒前
8秒前
8秒前
8秒前
8秒前
8秒前
星辰大海的应助被溪溪溪采纳,获得10
9秒前
橙橙橙橙完成签到 ,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163978
求助须知:如何正确求助?哪些是违规求助? 9558081
关于积分的说明 21743432
捐赠科研通 7754670
什么是DOI,文献DOI怎么找? 3428435
关于科研通互助平台的介绍 2553053
邀请新用户注册赠送积分活动 2473077